(Total Views: 373)
Posted On: 06/27/2019 4:59:00 AM
Post# of 153907
Plavac - during our mono , phase 3 mono , patients continue their HAART for the first week of study together with Leronlimab
After the first week HAART is stop and patient continue only with Leronlimab to the end of the study .
The first week when patient is on both HAART and Leronlimab is call overlap .
Few months ago company discovered that half life of Leronlimab is 10 days and not 3 they though , so they tried longer overlap , few weeks and not only one ,and efficacy was much improved .
They have 95% with 525 .
With combo HAART is never stopped , so there is no overlap.
Answering post about combo , I by mistake was talking about mono study and overlap .
I am not sure if this what you are asking about , so please let me know .
After the first week HAART is stop and patient continue only with Leronlimab to the end of the study .
The first week when patient is on both HAART and Leronlimab is call overlap .
Few months ago company discovered that half life of Leronlimab is 10 days and not 3 they though , so they tried longer overlap , few weeks and not only one ,and efficacy was much improved .
They have 95% with 525 .
With combo HAART is never stopped , so there is no overlap.
Answering post about combo , I by mistake was talking about mono study and overlap .
I am not sure if this what you are asking about , so please let me know .
(0)
(0)
